Physician profile

Anne E Hamilton

Acute Care (Nurse Practitioner) · Baltimore, MD

NPI 1730797127

$940.80

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$422.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $134.52 2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $129.08 2022-2023 Lifevest
Alexion Pharmaceuticals, INC. $122.37 2023 Ultomiris
Dexcom, INC. $121.15 2023 Dexcom G7 Gss (161)
Amarin Pharma, INC. $119.86 2023
Abbvie INC. $98.25 2022
Novo Nordisk INC $97.93 2021
Biogen, INC. $92.69 2022
Atricure, INC. $24.95 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anne E Hamilton

$940.80

in general payments reported 2019-2025

Years
2021-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/10935281/anne-e-hamilton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.